NCT05419765 - Lysosomal Acid Lipase Activity in Nonalcoholic Fatty Liver Disease | Biotech Hunter

Enrollment

316

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

January 31, 2023

Study Completion Date

March 31, 2023

Conditions

Non-Alcoholic Fatty Liver Disease

Interventions

DIAGNOSTIC_TEST

Peripheral blood withdrawn

"Peripheral blood will be withdrawn in order to measure haematic lipids (total cholesterol and fractions, triglycerides), total blood LAL activity, to perform genetic analysis and finally to evaluate lipase activity into the platelets.~Hepatic elastography will be also executed, in 100 patients, according to the presence/absence of the PNPLA3 variant, in order to weigh up the genetic predisposition on NAFLD development or progression"

Trial Locations (1)

00185

Department of Translational and Precision Medicine, Sapienza University of Rome, Umberto I Hospital, Rome